×
About 223 results

ALLMedicine™ Acute Megakaryoblastic Leukemia Center

Research & Reviews  86 results

Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 an...
https://doi.org/10.1182/blood.2021011463
Blood Hasle H, Kline RM et. al.

Nov 11th, 2021 - Individuals with Down syndrome are at increased risk of myeloid leukemia in early childhood associated with acquisition of GATA1 mutations that generate a short GATA1 isoform called GATA1s. Germline GATA1s generating mutations result in congenital...

Cohesin mutations in myeloid malignancies.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394903
Blood Jann JC, Tothova Z

Jun 23rd, 2021 - Cohesin is a multisubunit protein complex that forms a ring-like structure around DNA. It is essential for sister chromatid cohesion, chromatin organization, transcriptional regulation, and DNA damage repair and plays a major role in dynamically s...

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02530619

May 26th, 2021 - PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populati...

Outcome and Prognostic Features in Pediatric Acute Megakaryoblastic Leukemia Without Do...
https://doi.org/10.1016/j.clml.2020.11.001
Clinical Lymphoma, Myeloma & Leukemia; Wang Y, Lu A et. al.

Dec 2nd, 2020 - Acute megakaryoblastic leukemia (AMKL) is a biologically heterogeneous subtype of acute myeloid leukemia that originates from megakaryocytes. Patients with AMKL with non-Down syndrome (DS) had a poorer prognosis. However, clear prognostic indicato...

see more →

Clinicaltrials.gov  2 results

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02530619

May 26th, 2021 - PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populati...

A Pilot Study of ODSH in Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02056782

Feb 16th, 2015 - This is an open-label, multi-center, 10 patient pilot study with an anticipated 1 year enrollment period Primary Objectives: To evaluate the safety and tolerability of ODSH in patients with Acute Myeloid Leukemia (AML) receiving cytarabine and ida...

see more →

News  1 results

Team identifies new mechanism of megakaryocyte differentiation
https://www.mdedge.com/hematology-oncology/article/188547/leukemia-myelodysplasia-transplantation/team-identifies-new-mechanism
HT Staff

Jan 13th, 2016 - Megakaryocytes in the bone marrow Investigators have discovered a new mechanism of megakaryocyte differentiation, according to a paper published in eLife. They found that overexpression of the methyltransferase enzyme PRMT1 in acute megakaryocytic.

see more →